Literature DB >> 35734207

Elevated Levels of Urinary Biomarkers TIMP-2 and IGFBP-7 Predict Acute Kidney Injury in Neonates after Congenital Heart Surgery.

Michelle Ramírez1, Sujata Chakravarti1, Melissa Busovsky-McNeal1, Jaclyn McKinstry1, Yasir Al-Qaqaa1, Raj Sahulee1, T K Susheel Kumar2, Xiaochun Li3, Judith D Goldberg3, Ashley M Gefen4, Laura Malaga-Dieguez5.   

Abstract

Objectives  This article investigated the utility of urine biomarkers tissue inhibitor of metalloproteinase-2 (TIMP-2) and insulin-like growth factor binding protein-7 (IGFBP-7) in identifying acute kidney injury (AKI) in neonates after congenital heart surgery (CHS). TIMP-2 and IGFBP-7 are cell cycle arrest proteins detected in urine during periods of kidney stress/injury. Methods  We conducted a single-center, prospective study between September 2017 and May 2019 with neonates undergoing CHS requiring cardiopulmonary bypass (CPB). Urine samples were analyzed using NephroCheck prior to surgery and 6, 12, 24, and 96 hours post-CPB. All patients were evaluated using the Acute Kidney Injury Network (AKIN) criteria. Wilcoxon rank sum tests were used to compare the medians of the [TIMP-2*IGFBP-7] values in the AKIN negative and positive groups at each time point. Receiver operating characteristic curves were used to measure how well the [TIMP-2*IGFBP-7] values predict AKIN status. Results  Thirty-six patients were included. No patients met the AKIN criteria for AKI preoperatively. Postoperatively, 19 patients (53%) met the AKIN criteria for AKI diagnosis: 13 (36%) stage 1, 5 (14%) stage 2, and 1 (3%) stage 3. None required renal replacement therapy. At the 24-hour time points, patients who met the AKIN criteria for AKI had a statistically significantly higher [TIMP-2*IGFBP7] values than the patients without AKI (1.1 vs. 0.27 [ng/mL] 2 /1,000) at 24 hours (adj- p  = 0.0019). Conclusion  AKI is a serious complication associated with adverse outcomes in patients undergoing cardiac surgery. [TIMP-2*IGFBP-7] urinary level 24 hours after CPB is a good predictor of AKI in this population. Thieme. All rights reserved.

Entities:  

Keywords:  acute kidney injury; biomarkers; cardiopulmonary bypass; heart defects, congenital; insulin-like growth factor binding proteins; tissue inhibitor of metalloproteinase-2

Year:  2021        PMID: 35734207      PMCID: PMC9208843          DOI: 10.1055/s-0041-1740359

Source DB:  PubMed          Journal:  J Pediatr Intensive Care        ISSN: 2146-4626


  26 in total

Review 1.  Defining acute renal failure: physiological principles.

Authors:  Rinaldo Bellomo; John A Kellum; Claudio Ronco
Journal:  Intensive Care Med       Date:  2003-11-15       Impact factor: 17.440

2.  Risk factors for and outcomes of acute kidney injury in neonates undergoing complex cardiac surgery.

Authors:  Catherine J Morgan; Michael Zappitelli; Charlene M T Robertson; Gwen Y Alton; Reg S Sauve; Ari R Joffe; David B Ross; Ivan M Rebeyka
Journal:  J Pediatr       Date:  2012-08-09       Impact factor: 4.406

3.  TIMP-2*IGFBP7 (Nephrocheck®) Measurements at Intensive Care Unit Admission After Cardiac Surgery are Predictive for Acute Kidney Injury Within 48 Hours.

Authors:  Mehmet Oezkur; Attila Magyar; Phillip Thomas; Tabea Stork; Reinhard Schneider; Constanze Bening; Stefan Störk; Peter U Heuschmann; Rainer G Leyh; Martin Wagner
Journal:  Kidney Blood Press Res       Date:  2017-07-27       Impact factor: 2.687

4.  Congenital heart surgery in infants: effects of acute kidney injury on outcomes.

Authors:  Joshua J Blinder; Stuart L Goldstein; Vei-Vei Lee; Alixandra Baycroft; Charles D Fraser; David Nelson; John L Jefferies
Journal:  J Thorac Cardiovasc Surg       Date:  2011-07-27       Impact factor: 5.209

5.  Incidence, risk factors, and outcomes of acute kidney injury after pediatric cardiac surgery: a prospective multicenter study.

Authors:  Simon Li; Catherine D Krawczeski; Michael Zappitelli; Prasad Devarajan; Heather Thiessen-Philbrook; Steven G Coca; Richard W Kim; Chirag R Parikh
Journal:  Crit Care Med       Date:  2011-06       Impact factor: 7.598

6.  Quantification of urinary TIMP-2 and IGFBP-7: an adequate diagnostic test to predict acute kidney injury after cardiac surgery?

Authors:  Anna J Wetz; Eva M Richardt; Saskia Wand; Nils Kunze; Hanna Schotola; Michael Quintel; Anselm Bräuer; Onnen Moerer
Journal:  Crit Care       Date:  2015-01-06       Impact factor: 9.097

7.  Cell-Cycle Arrest Biomarkers: Usefulness for Cardiac Surgery-Related Acute Kidney Injury in Neonates and Infants.

Authors:  Mirela Bojan; Laurence Pieroni; Michaela Semeraro; Marc Froissart
Journal:  Pediatr Crit Care Med       Date:  2020-06       Impact factor: 3.624

8.  Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury.

Authors:  Kianoush Kashani; Ali Al-Khafaji; Thomas Ardiles; Antonio Artigas; Sean M Bagshaw; Max Bell; Azra Bihorac; Robert Birkhahn; Cynthia M Cely; Lakhmir S Chawla; Danielle L Davison; Thorsten Feldkamp; Lui G Forni; Michelle Ng Gong; Kyle J Gunnerson; Michael Haase; James Hackett; Patrick M Honore; Eric A J Hoste; Olivier Joannes-Boyau; Michael Joannidis; Patrick Kim; Jay L Koyner; Daniel T Laskowitz; Matthew E Lissauer; Gernot Marx; Peter A McCullough; Scott Mullaney; Marlies Ostermann; Thomas Rimmelé; Nathan I Shapiro; Andrew D Shaw; Jing Shi; Amy M Sprague; Jean-Louis Vincent; Christophe Vinsonneau; Ludwig Wagner; Michael G Walker; R Gentry Wilkerson; Kai Zacharowski; John A Kellum
Journal:  Crit Care       Date:  2013-02-06       Impact factor: 9.097

9.  Acute kidney stress--a useful term based on evolution in the understanding of acute kidney injury.

Authors:  Nevin Katz; Claudio Ronco
Journal:  Crit Care       Date:  2016-01-22       Impact factor: 9.097

10.  TIMP2•IGFBP7 biomarker panel accurately predicts acute kidney injury in high-risk surgical patients.

Authors:  Kyle J Gunnerson; Andrew D Shaw; Lakhmir S Chawla; Azra Bihorac; Ali Al-Khafaji; Kianoush Kashani; Matthew Lissauer; Jing Shi; Michael G Walker; John A Kellum
Journal:  J Trauma Acute Care Surg       Date:  2016-02       Impact factor: 3.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.